ArticleBritish journal of cancer2026

Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

Yvette Drew et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.